

## **PRESS RESELAASE**

Malmö, 29 March 2019

### **Change in number of shares and votes in Ascelia Pharma AB (publ)**

**During March, the registered number of shares and votes in Ascelia Pharma AB (publ) has increased due to the new issue that was executed in connection with the listing of the company's shares on Nasdaq Stockholm. As of 29 March 2019, the registered number of shares and votes in Ascelia Pharma AB (publ) amounts to 22,606,891.**

**For more information, please contact**

Magnus Corfitzen, CEO

Email: [moc@ascelia.com](mailto:moc@ascelia.com)

Tel: +46 735 179 110

Mikael Widell, IR & Communications Manager

Email: [mw@ascelia.com](mailto:mw@ascelia.com)

Tel: +46 703 11 99 60

*This information is such information as Ascelia Pharma AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 5.15 p.m. CET on 29 March 2019.*

#### **About Ascelia Pharma**

Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company's strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit [www.ascelia.com](http://www.ascelia.com)